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Theb-amyloid peptide @A4), derived from a larger amyloid precursor protein, is the principal component of senile plaques in Alzheimer’s disease. 
Here we report that the full-length (l-40) synthetic /3A4 peptide, containing one glutamine and two lysine residues, is able to form homopolymers 
in a transglutaminase-mediated reaction. Moreover, transglutaminase catalysed the formation of heteropolymers in reactions of /?A4 with a,M 
receptor, a constituent of amyloid plaques, and with extracellular matrix proteins. Incorporation of site-specific probes followed by enzymatic 
digestion and sequencing of tracer-containing fractions demonstrated that both Lys I6 Lys2* and Gin” in /?A4 were susceptible tocross-linking by ,
transglutaminase. 
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1. Introduction 
A prominent feature of Alzheimer’s disease (AD) is the 
presence of amyloid-bearing senile plaques in the brain. 
The principal protein component of the amyloid deposits 
has been characterized as a 39-42 residues peptide, 
known as /?A4 [1,2]. The /IA4 peptide is derived from a 
larger membrane-spanning glycoprotein, the amyloid 
precursor protein (APP), which is expressed as multiple 
different mRNA splicing products (for review see [3]). 
Two main APP processing pathways have been de- 
scribed, one secretory [4-61 and one endocytic [7-91. APP 
processing by the secretory pathway involves a cleavage 
in the /3A4 region, releasing the soluble extramembra- 
nous portion and retaining a small fragment in the mem- 
brane. The endocytic pathway, in contrast, generates C- 
terminal fragments containing intact j?A4. /?A4 is a nor- 
mal proteolytic product of APP and is present in the 
cerebrospinal fluid of AD patients and controls [IO,1 11. 
Recently, /?A4 in multimeric forms as well as in aggre- 
gates with glycoproteins has been found to be constitu- 
ents of AD neuritic plaques [12]. Transglutaminase activ- 
ity has been detected in the brain and characterized as 
a tissue transglutaminase [ 13,141. Transglutaminases 
(TG) (EC 2.3.2.13) are Ca2’-dependent enzymes capable 
of forming covalent .+(y-glutamyl)lysine cross-links be- 
tween proteins containing reactive lysines and gluta- 
mines (for review, see [ 151). It has been proposed that TG 
is involved in the development of abnormal protein- 
aceous deposits in neurons [13] and is able to cross-link 
neuronal proteins [14]. To assess whether TG could take 
part in the amyloidogenic processes in AD, we examined 
full-length (l-40) /?A4 peptide as a substrate for trans- 
glutaminases. While this work was in progress, Ikura et 
al. [26] reported that a partial-length (l-28) /?A4 peptide 
formed homopolymers in the presence of TG. In this 
report, we show that /?A4 in a TG-catalysed reaction is 
able to homopolymerize and to form heteropolymers 
with extracellular matrix proteins as well as a,M recep- 
tor, a recently discovered protein in neurons [16] and in 
AD plaques [17]. Furthermore, TG-reactive glutamine 
and lysine residues in /?A4 were localized using site-spe- 
cific probes. 
*Corresponding author. Fax: (45) (86) 131 160. 2. Experimental 
Abbreviations: AD, Alzheimer’s disease; APP, amyloid precursor pro- 
tein; /?A4, /&amyloid peptide; Dns-peptide, dansyl conjugated to Pro- 
Gly-Gly-Gin-Gin-Be-Val; PTH, phenylthiohydantoin; TG, transglu- 
taminase; a,M receptor, a,-macroglobulin receptor. 
2.1. Reagents 
Amyloid&xptide (amino acids l-40) was purchased from Bachem, 
Switzerland. The/IA4 was iodinated by incubating2pgBA4 in 100 mM 
NaCI, 70 mM NaH,PO,, pH 8.0,0.07% Triton X-100 with 0.2 mCi lZ51 
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and 2.5 mg/ml chloramine-T for 1 min at 20°C. The incorporation was 
terminated by chromatography on a 2 ml Sephadex G-25 column equil- 
ibrated in 150 mM NaCl, 0.6 mM CaCl,, 10 mM NaH,PO,, pH 7.4, 
0.1% Triton X-100. The tracer had a specific activity of 20 mCi/mg. The 
dansylated peptide (dansyl-Pro-Gly-Gly-Gln-Gin-Be-Val) (Dns-pep- 
tide) was synthesized at Kern-En-Tee, Denmark. Guinea pig liver 
transglutaminase and thermolysin were from Sigma, USA. Human 
placental factor XIII zymogen, was purified from Fibrogammin (Beh- 
ringwerke, Germany, a gift from Dr. E. Schiiler) and activated by brief 
exposure to 0.5 M CaCl, according to [18]. [1,4-‘4C]putrescine (109 
mCi/mmol), [1,4-‘Hlputrescine (20 Cilmmol) and “‘1 (2.0 Ciipmol) 
were from Amersham, UK. The molecular weight markers were from 
Boehringer Mannheim, Germany. 
2.2. Transglutaminase-mediated homo- and heteropolymerization ofSAl 
All polymerization experiments were carried out in 50 mM Tris, pH 
8.5. 0.5 mM DTE. 5 mM CaCl,. and for inhibition of TG-mediated 
cross-linking either 5 mM EDTA or 50 mM putrescine were added. 
Homopolymerization was performed with 5 PM /IA4 supplemented 
with ‘Z51-labelled @A4 (5 x lo6 cpm/ml) in the presence of 0.1 PM guinea 
pig liver tissue TG. Incubations were terminated by denaturation in 
reducing SDS-sample buffer, heated at 95°C for 5 min prior to analysis 
by SDS-PAGE using 16% Tris-Tricine gel electrophoresis [19]. 
Heteropolymerization, according to Jensen et al. [20], was performed 
with murine basement membrane proteins (Matrigel, Collaborative 
Research, Inc., USA) and purified a,M receptor stripped for the 40 kDa 
a,M receptor associated protein by heparin-Sepharose chromatogra- 
phy [21], in a concentration of 50 pg/ml. The a,M receptor preparation 
was a pure I@ chain preparation as judged by silver staining of SDS- 
PAGE resolved material in agreement with Moestrup and Gliemann 
[21]. The resulting labelled polymers were analysed by SDS-PAGE 
using either 16% Tris-Tricine or S-16% gradient Tris-glycine gels [22] 
followed by autoradiography. 
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Fig. 1. Transglutaminase-catalysed formation of /IA4 homopolymers 
and cross-linking to a,M receptor and extracellular matrix proteins. 
Panel A: Homopolymerization. 5 pM/JA4 supplemented with [“‘I]BA4 
(5 x lo6 cpmlml) (lane 1) were incubated with 0.1 PM guinea pig liver 
TG in 50 mM Tris, pH 8.5,0.5 mM DTE, 5 mM CaCl, for 5 min (lane 
2) and 60 min (lane 3). Lanes 4 and 5 show incubation with TG for 60 
min in the presence of 5 mM EDTA and 50 mM putrescine, respec- 
tively. The incubations were terminated by denaturation in reducing 
SDS-sample buffer, heated at 95°C for 5 min prior to analysis by 
SDS-PAGE using 16% Tris-Tricine gel electrophoresis. The autoradio- 
gram is presented with the molecular mass markers x 10L3 shown to the 
left. Panel B: Cross-linking to azM receptor and extracellular matrix 
proteins. ‘251-labelled PA4 (5 x lo6 cpm/ml) was incubated with TG as 
in panel A, for 45 min (lane l), supplemented with 50 &ml purified 
cc,M receptor (lane 3) or 50 .&g/ml extracellular matrix proteins (lane 
4). The effect of 5 mM EDTA on the polymerization in lane 1 and 4 
is shown in lanes 2 and 5, respectively. The samples were analysed using 
8-16% Tris-glycine gradients gels. The autoradiogram ispresented with 
the molecular mass markers x lo-’ shown to the left. The arrow marks 
the interphase between the stacking gel and the resolving gel. 
2.3. Labelling of /IA4 with site-specific probes 
In the glutamine-labelling experiment, PA4 (100 fig at a concentra- 
tion of 5 PM) was labelled with 13 &i/ml [‘4C]putrescine and 20 pCi/ml 
[‘Hlputrescine, at a final putrescine concentration of lOOpM, by guinea 
pig liver transglutaminase (50 nM) in 50 mM Tris, pH 8.5,5 mM CaCI,, 
0.5 mM DTE at 37°C for 24 h. The reaction was stopped by precipita- 
tion in 20% trichloroacetic acid. The precipitate was washed with ace- 
tone in order to remove unincorporated radiolabelled putrescine. Incor- 
poration of Dns-peptide was performed in 0.1 M Tris, 2.5 mM CaCl,, 
20 mM DTE, pH 8.5 using 1.74 PM Dns-peptide to 33 nmol PA4 (final 
concentrations). Guinea pig liver transglutaminase (2.3 nmol) was 
added and the mixture was incubated at 37°C for 18 h. 
2.4. Purification and characterization of radiolabelled-putrescine- and 
Dnslpeptide-labelled PA4 peptides 
DNS-nentide-labeled BA4 was nurified bv HPLC to remove unincor- 
porated bNS-peptides. ‘Fractions were analysed by SDS-PAGE using 
a 16% Tris-Tricine gel under reducing conditions. The gel was photo- 
graphed under UV-light and stained with Coomassie brilliant blue. 
Radiolabelled putrescine- and Dns-peptide-labelled pA were subjected 
to thermolysin digestion using an enzyme/substrate ratio of 1: 25 (w/w) 
in 0.1 M pyridine-acetate pH 6.5, 5 mM CaCI, at 55°C for 18 h. 
Separation of peptides was carried out by reverse-phase HPLC on a 
Pharmacia LKB HPLC svstem. Incornoration of radiolabelled vu- 
trescine was determined by liquid scintilation counting (Beckman’LS 
1801). Fluorescently labelled /IA4 and peptides were dissolved in Ep- 
pendorf tubes, visualized in UV-light and photographed. Automated 
Edman degradation was carried out on an ABI 477A/l20A protein 
sequencer (Applied Biosystems Inc., Foster City, USA) using standard 
programs. The small volume of the phenylthiohydantoin derivate sam- 
ple left over after on-line injection was used for radioactivity detection 
as described above. Peptides were hydrolyzed in 6 M HCl at 110°C for 
16 h in evacuated sealed tubes. The amino acid composition was deter- 
mined essentially as described by Barkholt and Jensen [23]. 
3. Results 
3.1. Homopolymerization of PA4 and cross-linking to 
C@ receptor and extracellular matrix proteins 
In Fig. 1 panel A, the ability of [“‘1]/3A4 to ho- 
mopolymerize in the presence of TG is shown by SDS- 
PAGE. The reaction was Ca2’-dependent (lane 4) and 
abrogated by the competitive inhibitor putrescine (lane 
5). The 4.2 kDa PA4 polymerized to multimeric forms of 
7.9 kDa, 11.9 kDa, 15 kDa and 18.8 kDa. Unlabelled 
PA4 polymerized to a similar extent as judged by silver 
staining of the gel. The polymerization was performed at 
a TG/substrate ratio of 1: 50 but could be carried out to 
a similar extent with a ratio of 1:200 (data not shown). 
Fig. 1, panel B demonstrates that the presence of a,M 
receptor (lane 3), a recently discovered constituent of 
amyloid plaques [ 171, and a mixture of extracellular ma- 
trix proteins (lane 4) enhanced the formation of TG- 
cross-linked ‘2SI-labelled /3A4 in a reaction sensitive to 
EDTA (lane 2 and lane 5). The results presented above 
were obtained using guinea pig liver transglutaminase. 
Furthermore, purified activated human FXIII catalysed 
the incorporation of radiolabelled-putrescine in PA4 in 
a Ca*‘-dependent reaction (data not shown). 
3.2. IdentiJication of transglutaminase acceptor and 
donor sites in PA4 
Radiolabelled putrescine and Dns-peptide were used 
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Fig. 2. Separation of a thermolysin digest of [‘4C]putrescine-labelled PA4 was digested with thermolysin. The resulting peptides were separated on 
a Vydac C,, (1Oflm) reverse-phase HPLC column using 0.05% heptafluoroacetic acid (solvent A) and 0.05% heptafluoroacetic acid in 80% acetonitrile 
(solvent B) with a stepwise linear gradient (...). The flow rate was 0.5 ml/min and the column temperature was 40°C. Peptides were detected in the 
effluent bv recording the absorbance at 226 nm (-) and collected manually. Hatched bars indicate total amount of radioactivity in the respective 
peaks as determined by liquid scintillation counting. 
as site-specific substrates for the TG-catalysed incorpo- 
ration of radioactive putrescine on the y-glutaminyl res- 
idues [24], and of the fluorescently dansylated peptide on 
the E-amino groups of lysines [25]. 
Only one major radioactively labelled peak was found 
in the thermolysin digest of [‘4C]putrescine-labelled /?A4 
(Fig. 2). Sequence analysis of this peak showed one 
major sequence: Val-His-His-Gln-Lys corresponding to 
residues 12-16 in BA4. In the sequence analysis a low 
yield of PTH-Gln was observed in cycle 4, indicating a 
putrescine-linked glutamine. Scintillation counting of the 
PTH-amino acids showed radioactivity in cycle 4, thus 
confirming incorporation of putrescine at Gin” (data 
not shown). 
The Dns-peptide-labelled /3A4 was purified by reverse- 
phase HPLC (Fig. 3A). The fractions were monitored by 
SDS-PAGE followed by fluorescent detection of the gel 
in UV-light (Fig. 3B, left) and subsequent staining with 
Coomassie brilliant blue (Fig. 3B, right). Coomassie 
staining of the last eluting fraction (peak 3) resulted in 
a -4 kDa band (lane 4 right) coinciding with a fluores- 
cent band (lane 4 left), thus showing that this fraction 
contained the Dns-peptide labelled /?A4. The major frac- 
tions eluting at approximately 40-45 min consisted of 
unincorporated Dns-peptide, since only fluorescent 
bands were observed (lane 3, left compared with lane 3, 
right). Lack of detectable bands in the Coomassie stained 
gel is due to the inability of the Dns-peptide to bind the 
dye. No fluorescent labelling of PA4 occurred in a con- 
trol experiment in which 50 mM EDTA was included 
(data not shown). 
The purified Dns-peptide-labelled /3A4 was digested 
with thermolysin and the resulting peptides were sepa- 
rated by reverse-phase HPLC (Fig. 4A). The fractions 
were evaporated, dissolved in 0.1% trifluoroacetic acid 
and the Dns-peptide containing fractions were visualized 
in UV-light (Fig. 4B). As seen, only peaks 3 and 6 were 
found to contain the fluorescent probe. Sequencing of 
peak 3 gave the sequence: Val-Gly-Ser-Asn-Xxx-Gly- 
Ala, where Xxx denotes that no PTH-amino acid was 
detected in that cycle. This sequence aligns with residues 
24-30 in BA4, assuming that the missing PTH-amino 
acid in cycle 5 is a Dns-peptide-linked lysine residue. 
Sequence analysis of peak 6 showed the sequence: Val- 
His-His-Gln-Xxx, indicating that this corresponds to 
residues 12-16 in /3A4 with a C-terminal Dns-peptide- 
linked lysine residue. Amino acid analysis verified the 
identities of the fluorescently labelled peptides, and fur- 
ther showed that the C-terminal Val residue of the Dns- 
peptide was cleaved off by thermolysin as would be ex- 
pected. Thus, we conclude that Gln15 as well as both 
Lys16 and Lys” in PA4 act as amine acceptor and donor 
sites, respectively, in a TG-mediated incorporation of 
site-specific probes. 
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Fig. 3. (A) Purification of Dns-peptide-labelled PA4 by HPLC. ,6A4 labelled with Dns-peptide was purified on a Vydac C,s (10 brn) reverse-phase 
HPLC column eluted with a stepwise linear gradient (. .) of 80% acetonitrile in 0.1% trifluoroacetic acid. The flow rate was 0.5 ml/min and the column 
temperature was 40°C. The eflluent was monitored at 226 nm (-). (B) Fractions were analysed by SDS-PAGE using a 16% Tris-Tricine gel under 
reducing conditions. The gel was photographed under UV-light (left) and stained with Coomassie brilliant blue (right). Lane I, molecular mass 
markers; lane 2, /IA4 peptide; lane 3, fraction 2; lane 4, fraction 3. 
4. Discussion 
The present results are in general agreement with the 
recent finding that a partial-length (l-28) /?A4 peptide is 
a substrate for TG [26]. Whether Lys16 and/or Lys” par- 
ticipate in the cross-linking of /?A4 remains to be eluci- 
dated. By using two modified versions of the partial- 
length /?A4 peptide (Lys16 or Lys2’ replaced by L-norleu- 
tine) Ikura et al. [26] found that Lys16 was involved 
exclusively in the polymerization. However, exclusion of 
Lys2* as a potential donor site is questionable, since this 
amino acid is positioned C-terminal in the partial-length 
peptide. DA4 being a TG-substrate might explain the 
presence of PA4 in large proteinaceous aggregates iso- 
lated from plaques [12]. 
TG-mediated cross-linking of PA4 may be relevant to 
amyloid deposition in AD. Cell membrane damage may 
be an early event in the disease [27] and certainly occurs 
as the lesions develop. This might cause an increase in 
the intracellular Ca2’ concentration and activation of 
TG, as well as a leak of cytosolic TG to the extracellular 
environment. Normal processing of APP occurs within 
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Fig. 4. (A) Separation of a thermolysin digest of Dns-peptide-labeled BA4. /?A4 labelled with the Dns-peptide was digested with thermolysin and 
the resulting peptides were separated by reverse-phase HPLC using the same conditions as in Fig. 2. (B) Fluorescent detection. The isolated peptides 
from the thermolysin digest were evaporated, dissolved in 0.1% trifluoroacetic acid and photographed under UV-light. Fluorescent-containing peaks, 
3 and 6 were subjected to amino acid composition and sequence analysis. 
the /IA4 sequence between Gin” and Lys16 or Lys16 and 
Leu17 [46]. Assuming APP like PA4 is a TG-substrate, 
cross-linking of Gin” and Lys16 might impair the normal 
secretase cleavage. Based on our results and integrating 
recent studies, we propose a working hypothesis for the 
formation and growth of senile plaques. In normal cells, 
normal processing of APP results in slow secretion of 
PA4 which is matched by an unknown clearance mecha- 
nism resulting in low extracellular /?A4. The initial steps 
of the abnormal processing of APP are generally un- 
known. However, extracellular /3A4 accumulation causes 
(i) significant binding of/?A4 to complement factor 1 and 
activation of the complement cascade [28] which dam- 
ages the cell, and (ii) precipitation of PA4 with compo- 
nents of plaques, e.g. ApoE4, a BACbinding protein 
[29,30] and cc,M [31]. Cross-links between some /IA4 
molecules and other TG-substrates e.g. a,M [32] are 
formed by activated TG. The cross-link-stabilized pre- 
cipitate presents several epitopes for binding to the 
multi-ligand and multi-site receptor ol,M receptor which 
is overexpressed in this state [17]. The endocytosis is 
thought to be partially futile because the j?A4 moieties 
are poorly degraded in lysosomes [33]. Finally, the cell 
dies, and debris including PA4 is embedded in senile 
plaques together with a,M receptor, apoE4, a,M and 
several other constituents. 
Future studies should show whether the multi- 
merit forms of /?A4 and aggregates found in AD 
brain are in fact the result of such transglutaminase r ac- 
tions. 
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